Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation
Advertisement
705 Mount Auburn offers both built out and shell lab space options along with a best-in-class onsite amenity package.
There were a number of real estate moves in Watertown recently, but before jumping in, we wanted to highlight the Watertown Business Coalitions’ upcoming Community STEM Night on April 29th in partnership with Watertown Public Schools. The event will give the community a window into the opportunities available for the next generation of scientists in Watertown, including industry mentorship programs like Watertown Colab. Partnerships are available and its a great opportunity to introduce your biotech to the local Watertown community. If you find events like these and our newsletters informative, consider supporting our work.
Triveni Bio Moves to Arsenal Yards
Triveni Bio, headquartered at 99 Coolidge Ave announced last week that they are moving to Arsenal Yards. They will occupy the top floor of 100 Forge, more than doubling their previous space, which was sublet from Matchpoint Therapeutics. Triveni is engineering antibodies to treat a range of immunology and inflammatory diseases. Their lead antibody, TRIV-509 is currently in Phase 2 clinical trials as a treatment for Atopic Dermatitis (AD also known as Eczema), a disease that Watertown based Kymera Therapeutics and Enanta Pharmaceuticals are also developing therapeutics for. Unlike Kymera, Enanta, or market leader Dupilumab which block inflammation signaling pathways, Triveni is targeting KLK5/7, enzymes that are over expressed in AD patients, which they hypothesize are the root cause of inflammation in AD. Triveni’s hypothesis has garnered interest from investors, raising more than $207 million in 2023 and 2024. They were named one of Fierce Biotech’s “2025 Fierce 15” last fall. Beyond their lead compound, Triveni is also developing TRIV-573, a bi-specific antibody inhibiting KLK5/7 and the IL-13 signaling pathway, and aims to move it to clinical trials for an undisclosed disease later in 2026.
Corner Therapeutics and Four Flagship Pioneering Companies Are Moving into to 99 Coolidge Ave
While 99 Coolidge Ave may be losing Triveni Bio, they are in the process of gaining 5 more tenants. Corner Therapeutics a company focused on improving the effectiveness of immunotherapies, filed a biotech permit indicating they are moving to 99 Coolidge Ave from the Arsenal on the Charles in May. Separately, according to building permits filed with the city of Watertown, Profound Therapeutics (p), Ampersand Biomedicines (p), Abiologics (p), and Repertoire Immune Medicines (p) are building out suites at 99 Coolidge Ave. These 4 companies are backed by Flagship Pioneering, an integrated venture capital firm/start up incubator which has spun out more than 80 biotech companies, the most notable being Moderna. The four companies above are all examples of platform biotechs, where the company’s main focus is a suite of drug discovery tools and technologies, rather than expertise in a specific disease. For example, Ampersand advertises their “AND” Platform of machine learning and antibody engineering tools to design bispecific antibody variants for a range of diseases. We will give an overview of each company once they have moved here, which according to initial biotech permit filings may be as early as July. Together, these leases should bring 99 Coolidge Ave to over 50% occupancy for the first time since it opened in 2023.
Flagship companies have had presence in Watertown for at least half a decade, starting with Inzen Therapeutics in 2021. They merged with Cygnal Therapeutics to form Sonata Therapeutics. (Incidentally, Cygnal’s CEO Pearl Huang went on to lead Dunad Therapeutics, which was headquartered at Cambridge Scientific’s Labs on Dexter Ave before moving to the Seaport last year.) Sonata was one of the original tenants at 99 Coolidge Ave, occupying the 5th floor before going out of business in 2024. They were replaced by another Flagship company, Empress Therapeutics, which wound down in 2025. Empress was replaced by Foghorn Therapeutics, a now publicly traded company that was (you guessed it) founded by Flagship.
The FDA grants a Fast Track Designation for REM-422
Remix Therapeutics (headquartered at Arsenal Yards) announced that the FDA had granted Fast Track designation for their lead compound REM-422, a small molecule RNA degrader being developed to treat adenoid cystic carcinoma (ACC). ACC is an aggressive, rare tumor of the adrenal glands (roughly 2 cases per million people in the US annually). There is no approved systemic therapy, with surgery being the main treatment for ACC. The Fast Track designation was granted based on Phase 1b clinical trial data of REM-422 in patients with ACC, and provides the company with more frequent FDA meetings, eligibility of accelerated approval, and rolling review of a new drug application. According to Remix, REM-422 works by preventing the excision of a poison exon in the MYB pre-mRNA during RNA processing, which leads to degradation of the mRNA and a reduction in the levels of the cancer-causing MYB protein. REM-422 is also being studied in clinical trials for the treatment of Acute Myeloid Leukemia and has Orphan Drug Designation orphan drug status for both AML and ACC from the FDA.
Quick Updates
Addgene’s Sequencing Deal
Addgene announced a new partnership with Plasmidsaurus to provide whole plasmid sequencing as part of the quality control procedures for Addgene’s plasmid repository.
Cash Flow Checks
As discussed in our last newsletter, both Acrivon Therapeutics and Neumora Therapeutics released their lasted public filings. Their cash runways remain relatively unchanged, projected to last through Q2 & Q3 of 2027 respectively. While they are on the low end of public Watertown biotechs, they still have two to three times the cash on hand as Werewolf did last fall.
People
Averna Therapeutics (headquartered at 134 Coolidge Ave), announced the appointment of Robert Mabry, Ph.D. as Chief Scientific Officer, and Richard Morris as Chief Financial Officer.
That’s it for now, back in two weeks with more Watertown biotech news!
